IP Library Granted Patent US 12,492,180
Granted Patent B2
US 12,492,180 · App. 17/416,983 · Granted Dec 9, 2025

Process and intermediates for the preparation of Voxelotor

Inventors: Juan José Ferreiro Gil (Boecillo-Valladolid, ES); Jesús Miguel Iglesias Retuerto (Boecillo-Valladolid, ES); Antonio Lorente Bonde-Larsen (Boecillo-Valladolid, ES)
Assignee: CURIA SPAIN, S.A.U.
C07D401/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,492,180
App. No.
17/416,983
Granted
Dec 9, 2025
Kind
B2
Abstract

The invention relates to a process for the preparation of Voxelotor, or a salt or solvate thereof, which comprises the use of a compound of formula (I) or (I′), or a salt or solvate thereof.

Claims (60)

1 . A process for preparing Voxelotor

or a salt or solvate thereof, comprising:

(a) reacting a compound of formula (I)

or a salt or solvate thereof, wherein

R 3 represents hydrogen or a hydroxyl protecting group,

R 4 and R 4 ′ are independently selected from C 1-6 alkyl and C 1-6 alkoxyl;

with a compound of formula (II)

 or a salt or solvate thereof, wherein X is selected from OH, Cl, Br, I, OTf, OTs and OMs;

 to obtain a compound of formula (IV)

or a salt or solvate thereof, and

(b) converting the compound of formula (IV), or a salt or solvate thereof, into Voxelotor or a salt or solvate thereof.

2 . Process according to claim 1 , wherein step (b) comprises:

reduction of the amide group in the compound of formula (IV), or a salt or solvate thereof, to the aldehyde; and

if needed (if R 3 is a hydroxyl protecting group), cleaving the hydroxyl protecting group either before or after the step of reduction of the amide group.

3 . Process according to claim 1 , wherein the compound of formula (II), or a salt or solvate thereof, is obtained by a process comprising reacting a compound of formula (III)

or a salt or solvate thereof, wherein

X is selected from OH, Cl, Br, I, OTf, OTs and OMs, and

Y is selected from Cl, Br, I, OTf and OMs;

with a compound of formula (VIII)

or a salt or solvate thereof, wherein each R 2 is independently selected from the group consisting of OH, C 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkoxyl, or together they form a C 2-3 alkylenedioxy group optionally substituted by C 1-6 alkyl, or a benzyldioxy group optionally substituted by C 1-6 alkyl, or the —B(R 2 ) 2 group is —BF 3 K.

4 . Process according to claim 1 , comprising:

reacting a compound of formula (III′)

or a salt or solvate thereof, wherein Y is selected from Cl, Br, I, OTf and OMs;

with a compound of formula (VIII)

or a salt or solvate thereof, wherein each R 2 is independently selected from the group consisting of OH, C 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkoxyl, or together they form a C 2-3 alkylenedioxy group optionally substituted by C 1-6 alkyl, or a benzyldioxy group optionally substituted by C 1-6 alkyl, or the —B(R 2 ) 2 group is —BF 3 K;

to obtain a compound of formula (II′)

or a salt or solvate thereof,

 converting the compound of formula (II′), or a salt or solvate thereof, into a compound of formula (II″)

or a salt or solvate thereof, wherein X is selected from Cl, Br, I, OTf, OTs and OMs, preferably Cl;

reacting the compound of formula (II″), or a salt or solvate thereof, with a compound of formula (I)

or a salt or solvate thereof, wherein

R 3 represents hydrogen or a hydroxyl protecting group, and

R 4 and R 4 ′ are independently selected from C 1-6 alkyl and C 1-6 alkoxyl;

to obtain a compound of formula (IV)

or a salt or solvate thereof; and

converting the compound of formula (IV), or a salt or solvate thereof, into Voxelotor or a salt or solvate thereof.

5 . A process for preparing Voxelotor

or a salt or solvate thereof comprising:

(a) reacting a compound of formula (I)

or a salt or solvate thereof, wherein

R 3 represents hydrogen or a hydroxyl protecting group,

R 4 and R 4 ′ are independently selected from C 1-6 alkyl and C 1-6 alkoxyl;

with a compound of formula (III)

or a salt or solvate thereof, wherein

X is selected from OH, Cl, Br, I, OTf, OTs and OMs, and

Y is selected from Cl, Br, I, OTf and OMs;

to obtain a compound of formula (V)

or a salt or solvate thereof,

(b) reacting the compound of formula (V), or a salt or solvate thereof,

with a compound of formula (VIII)

or a salt or solvate thereof, wherein each R 2 is independently selected from the group consisting of OH, C 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkoxyl, or together they form a C 2-3 alkylenedioxy group optionally substituted by C 1-6 alkyl, or a benzyldioxy group optionally substituted by C 1-6 alkyl, or the —B(R 2 ) 2 group is —BF 3 K;

to provide a compound of formula (IV)

or a salt or solvate thereof, and

(c) converting the compound of formula (IV), or a salt or solvate thereof, into Voxelotor or a salt or solvate thereof.

6 . Process according to claim 5 , wherein step (c) comprises:

reduction of the amide group in the compound of formula (IV), or a salt or solvate thereof, to the aldehyde; and

if needed (if R 3 is a hydroxyl protecting group), cleaving the hydroxyl protecting group either before or after the step of reduction of the amide group.

7 . Process according to claim 3 , wherein said reacting of a compound of formula (III), or a salt or solvate thereof, with a compound of formula (VIII), or a salt or solvate thereof, is carried out in the presence of Pd(amphos)Cl 2 .

8 . Process according to claim 4 , wherein said reacting of a compound of formula (III′), or a salt or solvate thereof, with a compound of formula (VIII), or a salt or solvate thereof, is carried out in the presence of Pd(amphos)Cl 2 .

9 . Process according to claim 5 , wherein said reacting of a compound of formula (V), or a salt or solvate thereof, with a compound of formula (VIII), or a salt or solvate thereof, is carried out in the presence of Pd(amphos)Cl 2 .

Assignments (2)
CHANGE OF NAME Recorded Nov 5, 2025
From: CRYSTAL PHARMA, S.A.U.
To: CURIA SPAIN, S.A.U.
Reel/Frame 073449/0630 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2021
From: FERREIRO GIL, JUAN JOSE; IGLESIAS RETUERTO, JESUS MIGUEL; BONDE-LARSEN, ANTONIO LORENTE
To: CRYSTAL PHARMA, S.A.U.
Reel/Frame 057724/0579 →